Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The patients presenting with acute pulmonary embolism and right ventricular dysfunction are at high risk for life-threatening events and must be identified in the emergency department for adequate care and hospital admission. Echocardiography can identify right ventricular dysfunction, but this test is not always available, and echocardiographic criteria of right ventricular dysfunction vary among published studies. The primary purpose of this protocol is to study the prognostic value of a cardiac biomarker, h-FABP (heart-type Fatty Acid-Binding Protein) , to identify in the emergency department the patients presenting with high risk pulmonary embolism. As secondary outcomes, H-FABP results will be compared to other cardiac biomarkers (BNP, troponin) and clinical score performances that have been previously studied to stratify the prognosis of patients with pulmonary embolism in the emergency department.
| Condition | Intervention |
|---|---|
|
Pulmonary Embolism |
Biological: Dosage de l'h-FABP |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Performances de l'h-FABP Pour Identifier dès Les Urgences Les Embolies Pulmonaires d'évolution défavorable |
- number of death by pulmonary embolism [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- life-threatening pulmonary embolism (cardiopulmonary arrest, shock, mechanical ventilation) [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- recurrent episode of pulmonary embolism [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- prognostic value of a clinical score (PESI), BNP and troponin in acute pulmonary embolism [ Time Frame: 1 month ] [ Designated as safety issue: No ]
| Enrollment: | 165 |
| Study Start Date: | September 2009 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
-
Biological: Dosage de l'h-FABP
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients with acute pulmonary embolism diagnosed in the emergency departement
Exclusion Criteria:
- patient under guardianship
- patient without social insurance
- pregnant women
- refusal to sign the consent
- myocardial infarction in the 10 days before pulmonary embolism
Contacts and Locations| France | |
| Hôpital Rangueil Service des urgences | |
| Toulouse, France, 31059 | |
| Principal Investigator: | Dominique LAUQUE, MD | University Hospital, Toulouse |
More Information
No publications provided
| Responsible Party: | University Hospital, Toulouse |
| ClinicalTrials.gov Identifier: | NCT01326507 History of Changes |
| Other Study ID Numbers: | 0900303, 2009-A00441-56 |
| Study First Received: | November 6, 2009 |
| Last Updated: | December 13, 2011 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by University Hospital, Toulouse:
|
pulmonary embolism Heart-type fatty acid-binding protein cardiac biomarkers risk stratification |
Additional relevant MeSH terms:
|
Embolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases |
Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on June 17, 2013